Targeting glutamine metabolism in PIK3CA mutant colorectal cancers

We recently reported that PIK3CA mutant colorectal cancers (CRCs) are addicted to glutamine through up-regulation of glutamate pyruvate transaminase 2 (GPT2). A GPT2 inhibitor suppresses in vivo growth of PIK3CA mutant, but not wild-type, CRCs. This study indicates that targeting glutamine may be an effective approach to treat CRCs with PIK3CA mutations.

• Publication year

  2016

• Venue

  Genes and Diseases

• Publication date

  2016-07-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.gendis.2016.09.001PMID 30258894PMCID 6153462
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer

  2016influential reference
• AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.

  2015cited by this paper
• Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer

  2014cited by this paper
• Convergent loss of PTEN leads to clinical resistance to a PI3Kα inhibitor

  2014cited by this paper
• Discovery and saturation analysis of cancer genes across 21 tumor types

  2014cited by this paper
• Glutamine and cancer: cell biology, physiology, and clinical opportunities.

  2013cited by this paper
• Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway

  2013cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper

• PI3K signaling-regulated metabolic reprogramming: From mechanism to application.

  2023cites this paper
• Targeting fuel pocket of cancer cell metabolism: A focus on glutaminolysis.

  2022cites this paper
• PIK3CA mutation affects the proliferation of colorectal cancer cells through the PI3K-MEK/PDK1-GPT2 pathway.

  2021cites this paper
• Study of the metabolic alterations in patulin-induced neoplastic transformation in normal intestinal cells.

  2021cites this paper
• Molecular processes mediating hyperhomocysteinemia-induced metabolic reprogramming, redox regulation and growth inhibition in endothelial cells

  2021cites this paper
• Shining a light on metabolic vulnerabilities in non-small cell lung cancer.

  2020cites this paper
• Deactivation of Glutaminolysis Sensitizes PIK3CA-Mutated Colorectal Cancer Cells to Aspirin-Induced Growth Inhibition

  2020cites this paper
• 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against PIK3CA-Mutant Colorectal Cancers

  2020cites this paper
• A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues.

  2020cites this paper
• Long noncoding RNA UCA1 promotes glutamine-driven anaplerosis of bladder cancer by interacting with hnRNP I/L to upregulate GPT2 expression

  2020cites this paper
• Clinical Significance of Serum Glutamine Level in Patients with Colorectal Cancer

  2019cites this paper
• Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo

  2019cites this paper
• GPT2 mutations in autosomal recessive developmental disability: extending the clinical phenotype and population prevalence estimates

  2019cites this paper